Analysis of Molecular Aberrations in Ovarian Cancer Allows Novel Target Identification

Kwai Wa Cheng, John P. Lahad, Gordon B. Mills

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The completion of the Human Genome Project and recent advances in functional genomic, proteomic, and high-throughput screening methodologies have provided powerful tools for determining the mechanisms of human diseases, including complex polygenic diseases such as ovarian cancer. These developments may eventually lead to individualized molecular medicine, which is the treatment of patients based on the underlying genetic defects in their tumours and their own genetic makeup. A plethora of novel therapeutic agents that act on specific molecular targets defined by cancer genetics are under development. There is thus a great deal of interest in determining how specific genes and proteins function in cancers, in order to further the understanding of cancer initiation and progression; to aid in identifying biomarkers, therapeutic targets, and determinants of drug responsiveness; and to progress the development of novel antitumour agents.

Original languageEnglish (US)
Pages (from-to)461-473
Number of pages13
JournalJournal of Obstetrics and Gynaecology Canada
Issue number5
StatePublished - 2004
Externally publishedYes


  • Genes
  • Microarray
  • Oncogenes
  • Ovarian neoplasms
  • Proteomics
  • Therapeutic target
  • Tumor suppressor

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Analysis of Molecular Aberrations in Ovarian Cancer Allows Novel Target Identification'. Together they form a unique fingerprint.

Cite this